ProfileGDS5678 / 1447728_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.473031
GSM967853U87-EV human glioblastoma xenograft - Control 21.4641
GSM967854U87-EV human glioblastoma xenograft - Control 31.470571
GSM967855U87-EV human glioblastoma xenograft - Control 41.437881
GSM967856U87-EV human glioblastoma xenograft - Control 51.433021
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 11.484161
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.460131
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.448071
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.445331
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.462791
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.449121
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.449741
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.461681
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.455341